FDA U.S. Approves APR APR-TD011 Research Drug for Large Herpes Epidermis to Be Certified as Orphan Drug
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, the(http://of the Researchof the Pharmaceutical(http://of the Swiss APR AppliedPharmaceutical s (http:// announced that the U.SFood andMedicines(http://Administration (
FDA(http://) has approved the company's agency ad-TD011, a research drug numbered APR-TD011 for the treatment of large herpes epidermis (EB) to be certified as an orphan drugAPR-TD011 is a low-profile acidox solution containing hypochloric acid, sprayed in the form of local external use, developed specifically for the treatment of EBBecause of its unique physical and chemical properties, APR-TD011 can be used to regulate the creatine microenvironment to prevent or reduce infection and inflammation, thereby accelerating the physiological healing of the wound The global EB market is estimated to be between $1 billion and $1.3 billion EB poses a significant burden on global health care In the United States, the cost of treatment for severely infected patients exceeds $300,000 per year, while for malnourished EB patients, the cost of wound care supplies can exceed $10,000 per month
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
